N/A
Completed N=298
Radiofrequency (RF) Ablation Prospective Outcomes Study
Pain, Chronic
Source: ClinicalTrials.gov NCT04673032 ↗
Enrolled (actual)
298
Serious AEs
14.8%
Results posted
Apr 2026
Primary outcomePrimary: Patient Global Impression of Change (PGIC) — 66; 78; 54; 13 Participants
Summary
The objective of this study is to compile real-world outcomes of Boston Scientific commercially approved radiofrequency (RF) ablation systems in the treatment of patients diagnosed with pain
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Patient Global Impression of Change (PGIC) |
66; 78; 54; 13; 9; 2 | — |
Eligibility Criteria
Key Inclusion Criteria
- Study candidate is scheduled to be treated with a commercially approved Boston Scientific RF system for pain per local Directions for Use (DFU)
- Signed a valid, IRB/EC/REB-approved informed consent form
Key Exclusion Criteria
- Meets any contraindications per locally applicable Directions for Use (DFU)
- Currently diagnosed with cognitive impairment, or exhibits any characteristic, that would limit study candidate's ability to assess pain relief or to complete study assessments
Data sourced from ClinicalTrials.gov (NCT04673032). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.